<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app22.us.archive.org';v.server_ms=246;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10330?contentType=xml', '20180610075509')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20180610075509/https://www.guideline.gov/summaries/downloadcontent/ngc-10330?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20180610075509/https://www.guideline.gov/summaries/downloadcontent/ngc-10330?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10330?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20180610075509" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20180413221356/https://www.guideline.gov/summaries/downloadcontent/ngc-10330?contentType=xml" title="13 Apr 2018"><strong>Apr</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 07:55:09 Jun 10, 2018">JUN</td>
		  <td class="f" nowrap="nowrap">Jul</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20180519041435/https://www.guideline.gov/summaries/downloadcontent/ngc-10330?contentType=xml" title="04:14:35 May 19, 2018"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 07:55:09 Jun 10, 2018">10</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930200347/https://www.guideline.gov/summaries/downloadcontent/ngc-10330?contentType=xml" title="30 Sep 2016"><strong>2016</strong></a></td>
		  <td class="c" id="displayYearEl" title="You are here: 07:55:09 Jun 10, 2018">2018</td>
		  <td class="f" nowrap="nowrap">2019</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20180610075509*/https://www.guideline.gov/summaries/downloadcontent/ngc-10330?contentType=xml" title="See a list of every capture for this URL">5 captures</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016 - 10 Jun 2018</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/archiveteam);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/archiveteam" target="_new"><span class="wm-title">Archive Team</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  <img align=right src="http://archiveteam.org/images/e/e6/Archiveteam.jpg" width=200> Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded into a large amount of related projects for saving online and digital history.
<p>
History is littered with hundreds of conflicts over the future of a community, group, location or business that were "resolved" when one of the parties stepped ahead and destroyed what was there. With the original point of contention destroyed, the debates would fall to the wayside. Archive Team believes that by duplicated condemned data, the conversation and debate can continue, as well as the richness and insight gained by keeping the materials. Our projects have ranged in size from a single volunteer downloading the data to a small-but-critical site, to over 100 volunteers stepping forward to acquire terabytes of user-created data to save for future generations.
<p>
The main site for Archive Team is at <a href="http://www.archiveteam.org">archiveteam.org</a> and contains up to the date information on various projects, manifestos, plans and walkthroughs.
<p>
This collection contains the output of many Archive Team projects, both ongoing and completed. Thanks to the generous providing of disk space by the Internet Archive, multi-terabyte datasets can be made available, as well as in use by the <a href="http://archive.org/web/web.php">Wayback Machine</a>, providing a path back to lost websites and work. 
<p>
Our collection has grown to the point of having sub-collections for the type of data we acquire. If you are seeking to browse the contents of these collections, the Wayback Machine is the best first stop. Otherwise, you are free to dig into the stacks to see what you may find.
<p>
<b>The Archive Team Panic Downloads</b> are full pulldowns of currently extant websites, meant to serve as emergency backups for needed sites that are in danger of closing, or which will be missed dearly if suddenly lost due to hard drive crashes or server failures. 
<p>
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/archivebot)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/archivebot" target="_new"><span class="wm-title">ArchiveBot: The Archive Team Crowdsourced Crawler</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  ArchiveBot is an IRC bot designed to automate the archival of smaller websites (e.g. up to a few hundred thousand URLs). You give it a URL to start at, and it grabs all content under that URL, records it in a WARC, and then uploads that WARC to ArchiveTeam servers for eventual injection into the Internet Archive (or other archive sites).
<p>
To use ArchiveBot, drop by #archivebot on EFNet. To interact with ArchiveBot, you issue commands by typing it into the channel. Note you will need channel operator permissions in order to issue archiving jobs. The dashboard shows the sites being downloaded currently.
<p>
There is a dashboard running for the archivebot process at <a href="http://www.archivebot.com">http://www.archivebot.com</a>.
<p>
ArchiveBot's source code can be found at <a href="https://github.com/ArchiveTeam/ArchiveBot">https://github.com/ArchiveTeam/ArchiveBot</a>.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10330?contentType=xml","2018-06-10",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013 Dec;94(6):640-5. [40 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23988873&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Note</strong>: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. </p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Note</strong>: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. The recommendations that follow are based on the previous version of the guideline.</p>
<p>The strength of therapeutic recommendations (Strong, Moderate, Optional) is defined at the end of the &quot;Major Recommendations&quot; field.</p>
<p><span style=&quot;text-decoration: underline;&quot;><strong>Gene: <em>DPYD</em></strong></span></p>
<p><strong>Genetic Test Interpretation</strong></p>
<p>Each named * allele is defined by the genotype at one or more specific single-nucleotide polymorphisms (Supplementary Table S1 online [see the &quot;Availability of Companion Documents&quot; field]). Dihydropyrimidine dehydrogenase (DPD) function associated with the most common allelic variants is summarized in Supplementary Table S2 online (see the &quot;Availability of Companion Documents&quot; field). Table 1 summarizes the assignment of the probable DPD phenotype on the basis of the * allele diplotypes, and these assignments are used to link genotypes with fluoropyrimidine dosing. Briefly, homozygotes of <em>*2A</em>, <em>*13</em>, and rs67376798 are considered deficient in DPD; heterozygotes for any combination of <em>*2A</em>, <em>*13</em>, and rs67376798 allele A (on the plus chromosomal strand) have intermediate or partial DPD activity; and those with none of these alleles are likely to have normal, high activity. <em>DPYD</em> alleles have been extensively studied in multiple geographically, racially, and ethnically diverse groups and are summarized in Supplementary Tables S3 and S4 online (see the &quot;Availability of Companion Documents&quot; field). Because of conflicting data or weak evidence for alleles other than <em>*2A</em>, <em>*13</em>, and rs67376798A, the original guideline document does not currently report dosing recommendations for other variants of <em>DPYD</em>. Reports of other variants and phenotypes are discussed in the Supplementary Material online (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><strong>Table 1. Assignment of Likely DPD Phenotype Based on Genotype</strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table 1. Assignment of Likely DPD Phenotype Based on Genotype&quot;>
    <thead>
        <tr>
            <th valign=&quot;top&quot;>Likely Phenotype</th>
            <th valign=&quot;top&quot;>Genotypes</th>
            <th valign=&quot;top&quot;>Examples of Diplotypes</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td valign=&quot;top&quot;>Homozygous for wild-type allele or normal, high DPD activity</td>
            <td valign=&quot;top&quot;>An individual carrying two or more functional (<em>*1</em>) alleles</td>
            <td valign=&quot;top&quot;><em>*1/*1</em></td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Heterozygote or intermediate activity (~3&amp;ndash;5% of patients); may have partial DPD deficiency; at risk for toxicity with drug exposure</td>
            <td valign=&quot;top&quot;>An individual carrying one functional allele (<em>*1</em>) plus one nonfunctional allele <em>(*2A</em>, <em>*13</em>, or rs67376798A)</td>
            <td valign=&quot;top&quot;><em>*1/*2A</em>; <em>*1/*13</em>; or *1/rs67376798</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Homozygous variant or mutant; DPD deficiency (~0.2% of patients); at risk for toxicity with drug exposure</td>
            <td valign=&quot;top&quot;>An individual carrying two nonfunctional alleles (<em>*2A</em>, <em>*13</em>, or rs67376798A)</td>
            <td valign=&quot;top&quot;>*2A/*2A; 13/*13; or rs67376798/rs67376798A</td>
        </tr>
    </tbody>
</table>
<p class=&quot;Note&quot;>DPD, dihydropyrimidine dehydrogenase</p>
<p><span style=&quot;text-decoration: underline;&quot;><strong>Drugs: Fluoropyrimidines</strong></span></p>
<p><strong>Dosage Recommendations</strong></p>
<p>Table 2 (below) summarizes the genetics-based dosing recommendations for <em>DPYD</em> genotype and fluoropyrimidines. The strength of the dosing recommendations is based on the facts that some variants (<em>DPYD*2A</em>, <em>*13</em>, and rs67376798) clearly affect DPD activity, DPD activity is clearly related to 5-fluorouracil clearance, and 5-fluorouracil exposure is associated with its toxic effects. Therefore, reduction of fluoropyrimidine dosage in patients with these variants may prevent severe and possibly life-threatening toxicities. However, available evidence does not clearly indicate a degree of dose reduction needed to prevent fluoropyrimidine-related toxicities. Supplementary Table S6 online (see the &quot;Availability of Companion Documents&quot; field) summarizes the effects of these variants on 5-fluorouracil clearance and DPD activity. Although the data suggest that patients with the <em>DPYD*2A</em> variant may need a greater dose reduction than a patient with the rs67376798 variant, it is unclear to what extent the dose should be reduced. Furthermore, patients who are heterozygous for the nonfunctional <em>DPYD</em> variants mostly demonstrate partial DPD deficiency (leukocyte DPD activity at 30% to 70% that of the normal population). Thus, the authors' recommendation is to start with at least a 50% reduction of the starting dose; followed by an increase in dose in patients experiencing no or clinically tolerable toxicity, to maintain efficacy; and a decrease in dose in patients who do not tolerate the starting dose, to minimize toxicities. An alternative is pharmacokinetic-guided dose adjustment (if available). Patients who are homozygous for <em>DPYD*2A</em>, <em>*13</em>, or rs67376798 may demonstrate complete DPD deficiency, and the use of 5-fluorouracil or capecitabine is not recommended in these patients. Because capecitabine and tegafur are converted to 5-fluorouracil and then metabolized by DPD, the clearance of and exposure to 5-fluorouracil, in addition to its toxic effects, are similar in patients with these variants.</p>
<p>The U.S. Food and Drug Administration (FDA) has added statements to the drug labels for 5-fluorouracil (topical only) and capecitabine that contraindicate use in patients with DPD enzyme deficiency. The FDA drug label also warns to use precaution with intravenous 5-fluorouracil in these patients. The Dutch Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for 5-fluorouracil, capecitabine, and tegafur (5-fluorouracil prodrug combined with uracil; not available in United States). The Working Group recommends the use of an alternative drug for homozygous carriers of a decreased-activity allele and a reduced dose or alternative drug to capecitabine or 5-fluorouracil for heterozygous carriers of a decreased-activity allele.</p>
<p>At the time of the writing of the original guideline document, there were no data available on the possible role of <em>DPYD*2A</em>, <em>*13</em>, or rs67376798 in 5-fluorouracil toxicities in pediatric patient populations; however, there is no reason to suspect that variant <em>DPYD</em> alleles would affect 5-fluorouracil metabolism differently in children as compared with adults.</p>
<p><strong>Table 2. Recommended Dosing of Fluoropyrimidines by DPD Phenotype</strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table 2. Recommended Dosing of Fluoropyrimidines by DPD Phenotype&quot;>
    <thead>
        <tr>
            <th valign=&quot;top&quot;>Phenotype (Genotype)</th>
            <th valign=&quot;top&quot;>Implications for Phenotypic Measures</th>
            <th valign=&quot;top&quot;>Dosing Recommendations</th>
            <th valign=&quot;top&quot;>Classification of Recommendations<sup>a</sup></th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td valign=&quot;top&quot;>Homozygous for wild-type allele, or normal, high DPD activity</td>
            <td valign=&quot;top&quot;>Normal DPD activity and &quot;normal&quot; risk for fluoropyrimidine toxicity</td>
            <td valign=&quot;top&quot;>Use label-recommended dosage and administration</td>
            <td valign=&quot;top&quot;>Moderate</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Heterozygous, or intermediate activity</td>
            <td valign=&quot;top&quot;>Decreased DPD activity (leukocyte DPD activity at 30%&amp;ndash;70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td>
            <td valign=&quot;top&quot;>Start with at least a 50% reduction in starting dose, followed by titration of dose based on toxicity<sup>b</sup> or pharmacokinetic test (if available)</td>
            <td valign=&quot;top&quot;>Moderate</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Homozygous, or deficient activity</td>
            <td valign=&quot;top&quot;>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td>
            <td valign=&quot;top&quot;>Select alternative drug</td>
            <td valign=&quot;top&quot;>Strong</td>
        </tr>
    </tbody>
</table>
<p class=&quot;Note&quot;>Fluoropyrimidines: 5-fluorouracil, capecitabine, and tegafur. DPD, dihydropyrimidine dehydrogenase.</p>
<p class=&quot;Note&quot;><sup>a</sup>Rating scheme is described in the &quot;Rating Scheme for the Strength of the Recommendations&quot; field.</p>
<p class=&quot;Note&quot;><sup>b</sup>Increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Definitions</span></strong>:</p>
<p><strong>Strength of Therapeutic Recommendations</strong></p>
<p><strong>Strong</strong>: The evidence is high quality and the desirable effects clearly outweigh the undesirable effects.</p>
<p><strong>Moderate</strong>: There is a close or uncertain balance as to whether the evidence is high quality and the desirable clearly outweigh the undesirable effects.</p>
<p><strong>Optional</strong>: The desirable effects are closely balanced with undesirable effects and there is room for differences in opinion as to the need for the recommended course of action.</p></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Cancer</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Prevention"/>
      <fieldvalue value="Risk Assessment"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Medical Genetics"/>
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Pharmacology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Pharmacists"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To provide information to allow the interpretation of clinical <em>DPYD</em> genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil, capecitabine, and tegafur)</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Patients requiring fluoropyrimidine chemotherapy</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Dosing of fluoropyrimidines (5-fluorouracil, capecitabine, and tegafur) based on <em>DPYD</em> genotype</p></div>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Rate and severity of fluoropyrimidine-related adverse events including toxicity </p></div>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Hand-searches of Published Literature (Secondary Sources)"/>
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A literature search of the PubMed database (1966 to March 2013) using the keywords ([DPD OR DPYD OR Dihydropyrimidine Dehydrogenase] AND [fluorouracil OR 5-FU OR fluoropyrimidines OR capecitabine OR tegafur] AND genotype) was performed and results were limited to those available in English. Further articles were found via the reference sections of reviews.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Weighting According to a Rating Scheme (Scheme Given)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>High</strong>: Evidence includes consistent results from well-designed, well-conducted studies.</p>
<p><strong>Moderate</strong>: Evidence is sufficient to determine effects, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies; generalizability to routine practice; or indirect nature of the evidence.</p>
<p><strong>Weak</strong>: Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information.</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Clinical Pharmacogenetics Implementation Consortium's (CPIC's) dosing recommendations (see Table 2 in the original guideline document) are based on weighting the evidence from a combination of preclinical functional and clinical data, as well as on some existing disease-specific consensus guidelines. Some of the factors that are taken into account include<em> in vivo</em> clinical outcome for reference drug, <em>in vivo</em> pharmacokinetic and pharmacodynamic (PK/PD) studies for reference drug, and <em>in vitro</em> enzyme activity with probe substrate only.</p>
<p>The evidence summarized in Supplemental Table S5 (see the &quot;Availability of Companion Documents&quot; field) is graded using a modified scale (see the &quot;Rating Scheme for the Strength of the Evidence&quot;).</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Overall, the dosing recommendations are simplified to allow rapid interpretation by clinicians. The authors chose to use a slight modification of a transparent and simple system for just three categories for recommendations adopted from the rating scale for evidence based recommendations on the use of retroviral agents found at <a href=&quot;http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf&quot; title=&quot;AIDSInfo Web site&quot; target=&quot;_blank&quot;>http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf</a> (see the &quot;Rating Scheme for the Strength of the Recommendations&quot; field).</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Strength of Therapeutic Recommendations</strong></p>
<p><strong>Strong</strong>: The evidence is high quality and the desirable effects clearly outweigh the undesirable effects.</p>
<p><strong>Moderate</strong>: There is a close or uncertain balance as to whether the evidence is high quality and the desirable clearly outweigh the undesirable effects.</p>
<p><strong>Optional</strong>: The desirable effects are closely balanced with undesirable effects and there is room for differences in opinion as to the need for the recommended course of action.</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The main benefit to the patient would be the potential to avoid toxicity by using either alternative therapy or lower fluoropyrimidine doses.</p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>The aim is to prevent the most severe and fatal instances of toxicity, but some patients who would not have experienced this degree of toxicity and who would have benefited from fluoropyrimidine therapy may be advised against it. Moreover, heterozygous patients who receive a lower dose of a fluoropyrimidine and who would not have experienced this degree of toxicity may not experience the full benefit of fluoropyrimidine therapy; therefore, it is important to increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy. Patients who proceed with 5-fluorouracil therapy may still experience lower-grade toxicity that may be acceptable and even necessary in order to achieve efficacy. Some patients without a variant <em>DPYD</em> allele may still experience severe toxicity due to other genetic, environmental, or other factors. </li>
    <li>A possible risk is the misreporting or misinterpretation of genotype test results. This mistake could be recorded in the patient record and could also influence further treatments. </li>
</ul>"/>
    </field>
  </section>
  <section secid="430" ordby="800" name="Contraindications">
    <field fieldid="144" ordby="805" id="431" name="Contraindications" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The U.S. Food and Drug Administration (FDA) has added statements to the drug labels for 5-fluorouracil (topical only) and capecitabine that contraindicate use in patients with DPD enzyme deficiency. The FDA drug label also warns to use precaution with intravenous 5-fluorouracil in these patients.</p></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Caveats: Appropriate Use and/or Potential Misuse of Genetic Tests</strong></p>
<p>The positive predictive value and negative predictive value of <em>DPYD*2A</em> genotyping to predict development of severe toxicity (grade 3) are ~50 and ~95%, respectively; however, taking into account other variant alleles, such as rs67376798 and <em>DPYD*13</em>, increases the positive predictive value to 62% (the negative predictive value remains unchanged). Furthermore, the sensitivity calculated in this study for this genotype test was only 31%; therefore, the absence of these variants does not rule out DPD defects. Although many additional variants of <em>DPYD</em> are known (see Supplementary Tables S1, S3, and S4 online [see the &quot;Availability of Companion Documents&quot; field]), the frequencies are often very low, and evidence for their functionality is limited.</p>
<p><strong>Disclaimer</strong></p>
<p>Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision making and to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases that are not specifically identified. Guidelines do not account for individual variations among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. CPIC assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of CPIC's guidelines or for any errors or omissions.</p></div>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Resources"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Getting Better"/>
      <fieldvalue value="Living with Illness"/>
      <fieldvalue value="Staying Healthy"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Safety"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013 Dec;94(6):640-5. [40 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23988873&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2013 Dec "/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="Clinical Pharmacogenetics Implementation Consortium - Independent Expert Panel"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This work was funded by NIH grants R24 GM61374, U01 GM092666, and U01 HL0105918. This work was also supported by the German Federal Ministry of Education and Research (BMBF grant 03 IS 2061C) and the Robert Bosch Foundation, Stuttgart, Germany.</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Authors</em>: KE Caudle, Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; CF Thorn, Department of Genetics, Stanford University Medical Center, Stanford, California, USA; TE Klein, Department of Genetics, Stanford University Medical Center, Stanford, California, USA; JJ Swen, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands; HL McLeod, Moffitt Cancer Center, Tampa, Florida, USA; RB Diasio, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; and M Schwab, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The authors declared no conflict of interest.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Note</strong>: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. </p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Available from the <a href=&quot;https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/&quot; title=&quot;Clinical Pharmacogenetics Implementation Consortium (CPIC) Web site&quot;>Clinical Pharmacogenetics Implementation Consortium (CPIC) Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following is available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Supplementary material, including tables and methodological information, is available from the <a href=&quot;https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/&quot; title=&quot;Clinical Pharmacogenetics Implementation Consortium (CPIC) Web site&quot;>Clinical Pharmacogenetics Implementation Consortium (CPIC) Web site</a>. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on July 9, 2014. The information was verified by the guideline developer on August 13, 2014.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p>
<p>CPIC<sup>&amp;reg;</sup> is a registered service mark of the <a href=&quot;http://www.hhs.gov/&quot; title=&quot;DHHS Web site&quot; target=&quot;_blank&quot;>U.S. Department of Health &amp;amp; Human Services (HHS)</a>.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 07:55:09 Jun 10, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 00:16:07 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 83.585 (3)
  esindex: 0.011
  captures_list: 104.439
  CDXLines.iter: 15.436 (3)
  PetaboxLoader3.datanode: 64.753 (4)
  exclusion.robots: 0.398
  exclusion.robots.policy: 0.378
  RedisCDXSource: 0.599
  PetaboxLoader3.resolve: 65.437
  load_resource: 107.368
-->